Primary Progressive Multiple Sclerosis study: SUN-627
Official title A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
ClinicalTrials.gov ID: NCT07840326
What this study is testing
What is SUN-627?
SUN-627 is an investigational oral tablet being studied as a potential treatment for primary progressive multiple sclerosis.
Also referred to as NEU-627, N-004850.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study is looking to see if SUN-627 is safe and tolerable for people with non‑active SPMS or PPMS.
- Who it's for
- Men or women ages 18 to 70 who have been diagnosed with non‑active secondary progressive or primary progressive multiple sclerosis.
- What's involved
- Participants will take SUN-627 and undergo regular safety checks and tests during the trial.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Aged 18-70, inclusive
- Diagnosis of PPMS or non-active SPMS
- No MS relapses in the past 2 years
- Evidence that MS has continued to get worse over time
- A level of disability that fits the study requirements
You likely can't join if
- Use of certain medications or treatments before the study, or need for these treatments during the study
- Current participation in another research study
- Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk
- Certain serious or unstable medical conditions that could make the study unsafe
- Active infection, recent infection, or a history of repeated infections Additional inclusion and exclusion criteria are outlined in the full study...
The study team makes the final eligibility decision.
Where it is enrolling
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Raleigh, North Carolina, United States
- Columbus, Ohio, United States
- Oklahoma City, Oklahoma, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Tampa, Florida, United States; Atlanta, Georgia, United States; Raleigh, North Carolina, United States; Columbus, Ohio, United States; Oklahoma City, Oklahoma, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.